Skip to main content

Table 1 Participant characteristics

From: Impaired cardiac and peripheral hemodynamic responses to inhaled β2-agonist in cystic fibrosis

 

Control

Cystic fibrosis

P

n

30

18

 

Age, years

27±2

22±2

0.04

Gender, male/female

18/12

13/5

0.54

Height, cm

172±2

167±2

0.07

Weight, kg

71±2

64±4

0.09

Body mass index, kg/m2

24±1

23±1

0.32

Body surface area, m2

1.8±0.0

1.7±0.1

0.04

Blood urea nitrogen, mg/dL

14.4±0.8

15.1±1.1

0.61

Serum creatinine, mg/dL

1.01±0.03

0.92±0.04

0.18

Serum sodium, mEq/L

139±0

138±1

0.11

Serum chloride, mEq/L

105±0

103±1

0.20

Albuterol dose (body weight standardized)

Mean, μg/kg

36±1.2

41.0±2.0

0.04

Functional capacity and physical activity

Peak oxygen uptake, mL/kg/min

35.1±2.1

23.7±2.2

<0.01

Peak oxygen uptake, % of predicted

97±6

55±5

<0.01

Exercise hours/week (self report)

7±1

9±3

0.23

Pulmonary function test parameters

Forced vital capacity (L)

4.6±0.2

3.7±0.3

0.01

Forced vital capacity (%predicted)

97.3±2.8

83.2±4.7

0.02

FEV1 (L)

3.7±0.1

2.7±0.3

<0.01

FEV1 (%predicted)

94.7±2.6

73.8±6.1

<0.01

FEV1/FVC

0.8±0.0

0.7±0.0

<0.01

FEF25-75 (L/sec)

3.7±0.1

2.2±0.4

<0.01

FEF25-75 (%predicted)

89.6±4.0

54.2±8

<0.01

Medications (n)

Bronchodilators (e.g. ProAir)

0

13

 

Taking >1 bronchodilator

0

4

 

Antibiotics (oral or inhaled)

0

14

 

Inhaled (e.g. Tobramycin)

0

9

 
  1. Data are mean±SEM or as n. FEV1, forced expiratory volume in one second; FEF25-75 = forced expiratory flow at 25.0 – 75.0 % of forced vital capacity